알림

Aldeyra Therapeutics Inc. (ALDX)

NasdaqCM: ALDX · 실시간 가격 · USD

1.56

+0.00 (0.00%)

종가 기준: Aug 17, 2026, 3:59 PM

0.00% (1D)

매수호가	1.11
시가총액	94.11M
매출 (ttm)	n/a
순이익 (ttm)	-23.05M
베타	1.20
EPS (ttm)	-0.38
P/E (ttm)	n/a
선행 P/E	-5.67
P/B (ttm)	2.48
P/S (ttm)	n/a
Earnings Date	Nov 4, 2026

매도호가	1.95
거래량	788,714
평균 거래량 (20일)	1,364,619
시가	1.55
전일 종가	1.56
일중 범위	1.52 - 1.58
52주 범위	1.07 - 6.17
애널리스트	Strong Buy
목표주가	7 (348.72%)
배당	n/a
배당락일	n/a

ALDX 소개

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. T...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 2, 2014

직원 수 6

상장 거래소 NasdaqCM

티커 ALDX

웹사이트 https://www.aldeyra.com

전체 기업 정보

재무 실적

2025년 Aldeyra Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -33.85M로, -39.4% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 4명의 투자의견을 종합하면 ALDX 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 7로, 최근 주가 대비 348.72% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Aldeyra Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.09 예상치 하회 -0.01, 및 43.75% 전년 대비 성장.

다음 실적 발표

Aldeyra Therapeutics Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2개월 전 · Simply Wall St.

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Investors who take an interest in Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) should definitely note that the CEO...

2개월 전 · MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, follow...

2개월 전 · Simply Wall St.

3 Promising Penny Stocks With Market Caps Reaching $300M

The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can ...

3개월 전 · Simply Wall St.

Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In th...

3개월 전 · Simply Wall St.

3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environm...

2 페이지 중 1

Aldeyra Therapeutics Inc. (ALDX)